# Skin & Aesthetics Peptide FAQ — GHK-Cu, GLOW — Auroa Peptides > Frequently asked questions about GHK-Cu and the GLOW research blend answered from the peer-reviewed literature, with citations. No dosing advice. Direct, citation-grounded answers to the questions readers most often bring to these two skin research peptides. ## What does a GHK-Cu peptide do? GHK-Cu acts as two things at once: a copper chaperone (a molecule that delivers copper to where it is needed) and a signaling molecule that tells skin cells to repair their scaffolding. At picomolar-to-nanomolar concentrations, it stimulates dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans and the proteoglycan decorin, while rebalancing the enzymes that degrade those matrix proteins [4]. The copper it carries also enables the lysyl-oxidase-mediated cross-linking that knits collagen and elastin fibers together. At the gene level, GHK has been shown to shift expression of roughly 31.2% of human genes (at a 50%-or-greater change threshold) toward repair, protein quality control and antioxidant programs [2]. ## What is GHK-Cu and how does it work? GHK-Cu is a three-amino-acid peptide (glycine-histidine-lysine) chelated one-to-one to a copper(II) ion. You will also see it called copper tripeptide-1. The GHK sequence occurs naturally within type I collagen — the main structural protein of skin and tendon — so the body already produces and recognizes this motif [4]. The copper coordination is required for most bioactivities; the free tripeptide GHK and the chelated copper complex GHK-Cu are different compounds with different properties, and most of the published research uses the copper form. Its mechanism involves direct fibroblast stimulation to produce collagen and elastin, copper delivery for enzymatic cross-linking, and broad gene-expression remodeling toward repair pathways [2][6]. ## Is GHK-Cu peptide really anti-aging? There is real, modest, and mostly topical human evidence for skin benefits. A 2015 review reports topical GHK-Cu increased collagen production in 70% of treated women, outperforming vitamin C (50%) and retinoic acid (40%), with placebo-controlled improvements in skin laxity, clarity, fine lines and wrinkle depth [4]. A 2025 review confirms procollagen synthesis up in 70% of GHK-Cu-treated subjects and evaluates delivery strategies [1]. Two honest limits: the widely repeated "~4,000 genes" figure overstates the verified result of roughly 2,100 genes at the 50%-change threshold [2], and the peptide penetrates intact skin poorly without delivery aids [1]. Systemic or whole-body "anti-aging" claims are unproven — all human data are from topical application. ## What is the difference between GHK and GHK-Cu? GHK is the bare tripeptide glycyl-histidyl-lysine. GHK-Cu is that same tripeptide chelated (firmly bound in a claw-like grip) to a copper(II) ion. The difference is not cosmetic — copper coordination is required for most of the compound's reported bioactivities: collagen cross-linking via lysyl oxidase, the antioxidant action, and most of the fibroblast signaling effects [4]. Secondary sources frequently conflate the two; a study using the free peptide cannot be assumed to produce the same results as one using the copper chelate. When this desk cites GHK-Cu research, it is the copper complex unless otherwise noted. ## What is GLOW peptide? GLOW is a multi-peptide research blend, not a single compound. It typically combines three distinct research peptides: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic fifteen-amino-acid peptide derived from a gastric protein), and TB-500 (a synthetic seven-amino-acid fragment of thymosin beta-4). Exact ratios vary by formulator — a commonly cited research label is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu, but this is not standardized. GLOW is not an approved drug anywhere, and no controlled study has tested the combination as a unit in humans [8][9]. ## What does the GLOW peptide do? The combination rationale is complementary repair coverage from three angles: GHK-Cu for matrix synthesis and collagen scaffolding [4], BPC-157 for pro-angiogenic (new-vessel) signaling via VEGFR2 upregulation [10], and TB-500 for actin-regulated cell migration and anti-scarring signals [8]. Community reports describe skin brightness, improved texture, faster wound healing and — carried over from the BPC-157/TB-500 component stacks — reduced joint and tendon discomfort. All community accounts are anecdotal, not from a controlled blend study, and never come with a verified dose. The blend's effects, if any, have never been tested in a peer-reviewed clinical trial. ## What does GLOW peptide have in it? GLOW typically contains three research peptides: (1) GHK-Cu, the copper-binding tripeptide (3 amino acids, MW approximately 402.9 Da); (2) BPC-157, a stable synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV (15 amino acids, MW approximately 1,419 Da) derived from a gastric body-protection protein; and (3) TB-500, the synthetic N-terminally acetylated heptapeptide Ac-LKKTETQ (7 amino acids, MW approximately 889 Da) corresponding to the actin-binding region of thymosin beta-4 [8]. Ratios and purity vary by source and are not standardized outside formal product analysis. ## What peptides are in the GLOW blend? The three constituent peptides are GHK-Cu (copper tripeptide-1), BPC-157 (body protection compound 157), and TB-500 (thymosin beta-4 fragment Ac-LKKTETQ). GHK-Cu contributes the matrix-building, copper-delivery and fibroblast-signaling mechanism [4][6]. BPC-157 contributes pro-angiogenic activity studied via VEGFR2 activation in animal models and human endothelial cells [10]. TB-500 contributes actin regulation and cell-migration promotion, with most efficacy data from the full-length thymosin beta-4 parent protein rather than the fragment itself [8]. Together the three are intended to cover matrix, blood supply and cell movement — but no study has confirmed they work synergistically when co-formulated [9]. ## Is GLOW banned in sport? Yes, effectively. Two of the three GLOW constituents are on the WADA Prohibited List. Thymosin beta-4 — the parent protein of the TB-500 fragment — is prohibited at all times under class S2 (peptide hormones, growth factors and related substances), which covers the TB-500 fragment. BPC-157 is prohibited under the S0 category for non-approved pharmacological substances, also at all times [8]. GHK-Cu is not currently itemized on the Prohibited List by name, but WADA's S0 catch-all category can apply to non-approved substances. Any athlete or person subject to anti-doping testing should treat the GLOW blend as prohibited and should not use it. ## Does GHK-Cu have side effects? Topical copper-peptide cosmetics have a long real-world safety record. Documented risks from the literature include: localized hyperpigmentation (skin darkening) in some topical applications — around 40% in one acne-scar microneedling study; formulation incompatibility with vitamin C (ascorbic acid) and low-pH acids, which can destroy both actives; and a theoretical copper-accumulation concern with prolonged systemic use, though no human copper-toxicity case attributed to GHK-Cu appears in the peer-reviewed record. For injectable or systemic use there is no validated human pharmacokinetic data, so the safety profile is genuinely unknown beyond small topical trials [1][3]. ## How does the GLOW blend compare to GHK-Cu alone? GHK-Cu as a standalone compound has real topical human evidence — small dermatology trials, a controlled hair-growth RCT, and decades of cosmetic use [3][4]. The GLOW blend adds two peptides with more data-poor human records (BPC-157 has three small human pilots; the TB-500 fragment has none) and layers in more significant regulatory and safety concerns [8][9]. Whether adding BPC-157 and TB-500 to GHK-Cu produces better skin outcomes than GHK-Cu alone is an untested question — the blend has never been studied in a controlled setting. The comparison page covers this in more detail. --- A measured digest of peer-reviewed skin and aesthetics peptide research — citations in hand, no products on offer.